Six airports currently participate in the volunteer COVID detection tests.
Over 1 billion travelers visit U.S. airports every year. For this reason, airline passengers are one of the most important populations to consider when it comes to identifying and tracking COVID and other pathogens.
The Traveler-based Genomic Surveillance Program (TGS), which is led by the Centers for Disease Control and Prevention’s (CDC) Travelers’ Health Branch has been collecting nasal swabs from international travelers since 2021. It currently operates at six airports in the U.S.
The CDC announced Tuesday that it will be adding Chicago O’Hare International Airport and Miami International Airport to its list of locations that participate in the program.
International travelers who wish to participate can stop at a testing station after their flight to self-administer a nasal swab and complete an anonymous, short survey about their trip. Samples are then sent to a laboratory where they undergo genome sequencing to detect COVID variants and other respiratory pathogens.
The program currently operates at six U.S. airports:
Since it launched in Sept. 2021, TGS has enrolled roughly 300,000 travelers per year from over 135 countries.
In addition to nasal swabs, the CDC has also been collecting wastewater from airplanes since Aug. 2022. At Dulles International Airport, samples are taken directly from the plane. At Boston Logan International Airport and JFK, samples are collected from the airport triturator, which is the wastewater collection point for multiple aircraft.
The CDC says that wastewater collection is a low-cost method that removes the need to interact with travelers who are potentially carrying pathogens.
Overall, TGS has been an effective early warning system and was able to detect multiple Omicron variants up to six weeks before other agencies in the U.S.
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More
Two Opdivo Updates from Bristol Myers Squibb
May 14th 2024First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.
Read More